KRYS - クリスタル・バイオテック (Krystal Biotech Inc.) クリスタル・バイオテック

 KRYSのチャート


 KRYSの企業情報

symbol KRYS
会社名 Krystal Biotech Inc (クリスタル・バイオテック)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Krystal Biotech Inc. is a gene therapy company. The Company is engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. The Company has developed a Skin TARgeted Delivery platform or STAR-D platform that consists of a patent pending engineered viral vector based on herpes simplex virus 1 or HSV-1 and skin-optimized gene transfer technology to develop off-the-shelf treatments for dermatological diseases. The Company’s products include KB103 and KB104.The Company''s KB103 is in preclinical development to treat dystrophic epidermolysis bullosa or DEB a rare and severe genetic disease. The Company''s KB104 is to treat Netherton Syndrome a severe form of ichthyosis which is a family of genetic skin disorders associated with thickened scaly skin and characterized by chronic skin inflammation itchiness and dehydration.   クリスタル・バイオテックは米国のバイオ医薬品企業。主に皮膚疾患に対する遺伝子治療の開発・商業化に従事する。同社はHSV-1に基づくウィルスベクタ―と皮膚最適化遺伝子導入技術プラットフォ―ム「STAR-D」を開発。重度の遺伝病であるジストロフィ―性表皮水疱症に対する遺伝子治療「KB-103」を開発する。本社所在地はペンシルベニア州ピッツバ―グ。   Krystal Biotech, Inc. is a gene therapy company, which engages in developing and commercializing treatment for patients suffering from dermatological diseases. It developed a gene therapy platform, which company refer to as the Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases for which company believe there are no known effective treatments. The company was founded by Suma M. Krishnan on April 15, 2016 and is headquartered in Pittsburgh, PA.
本社所在地 2100 Wharton Street Suite 701 Pittsburgh PA 15203 USA
代表者氏名
代表者役職名
電話番号 +1 412-586-5830
設立年月日 42339
市場名 NASDAQ Small Cap
ipoyear 2017年
従業員数
url www.krystalbio.com
nasdaq_url https://www.nasdaq.com/symbol/krys
adr_tso
EBITDA EBITDA(百万ドル) -8.25600
終値(lastsale) 15.51
時価総額(marketcap) 170282987.16
時価総額 時価総額(百万ドル) 234.93030
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 189.48030
当期純利益 当期純利益(百万ドル) -11.09200
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Krystal Biotech Inc revenues was not reported. Net loss increased from $1.3M to $4.4M. Higher net loss reflects Research and Development - Balancing increase from $698K to $2.9M (expense) General and Administrative - Balancing increase from $347K to $1.6M (expense) Stock-based Compensation in R&D increase of 82% to $122K (expense).

 KRYSのテクニカル分析


 KRYSのニュース

   Krystal biotech’s gene therapy an Orphan Drug in U.S. for cystic fibrosis (NASDAQ:KRYS)  2020/08/17 20:10:08 Seeking Alpha
The FDA has designated Orphan drug tag to Krystal Biotech (NASDAQ:KRYS), to KB407 for cystic fibrosis. KB407 is an inhaled, repeat-dose gene therapy produc
   Krystal Biotech’s KB407 Granted Orphan Drug Designation by the FDA to Treat Patients With Cystic Fibrosis  2020/08/17 20:01:00 GlobeNewswire
The company is on track to file an IND for KB407 in 2021
   Krystal Biotech Announces Initiation of Pivotal Phase 3 Study of Beremagene Geperpavec in Patients with Dystrophic Epidermolysis Bullosa  2020/07/28 20:44:49 GlobeNewswire
The randomized, double-blind GEM-3 trial will compare repeat dosing of either B-VEC or placebo in approximately 30 dystrophic epidermolysis bullosa (DEB)…
   Krystal Biotech Appoints Whitney Ijem as Senior Vice President, Strategy and Business Development  2020/07/20 12:00:00 GlobeNewswire
PITTSBURGH, July 20, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (Nasdaq:KRYS), a fully integrated gene therapy company driven by its proprietary,…
   The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight  2020/05/10 19:40:37 Benzinga
The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB ) gained about 6% for the week. Large-cap pharma names AstraZeneca plc (NYSE: AZN ) and Novartis AG (NYSE: NVS ) received FDA nods for their heart failure and lung cancer therapies, respectively. After receiving emergency use authorization from the FDA in the U.S., Gilead Sciences, Inc.'s (NASDAQ: GILD ) remdesivir obtained full regulatory approval in Japan. Moderna Inc (NASDAQ: MRNA ) received the OK to proceed with the Phase 2 trial of its mRNA coronavirus vaccine candidate mRNA-1273. The following are the key events and catalysts that biotech investors need to watch in the coming week. Conferences Bank of America Securities 2020 HealthCare Virtual Conference: May 12-14 American Society of Gene and Cell Therapy, or ASGCT, 23rd Virtual Annual Meeting: May 12-15 2020 Society for Investigative Dermatology, or SID, Annual Meeting Virtual Conference: May 13-16 Society for Cardiovascular Angiography and Interventions, or SCAI, 2020 Virtual Conference, Scientific Sessions: May 14-16 PDUFA Dates Clovis Oncology Inc (NASDAQ: CLVS ) awaits the FDA nod for an expanded indication for its cancer therapy Rubraca .
   Krystal biotech’s gene therapy an Orphan Drug in U.S. for cystic fibrosis (NASDAQ:KRYS)  2020/08/17 20:10:08 Seeking Alpha
The FDA has designated Orphan drug tag to Krystal Biotech (NASDAQ:KRYS), to KB407 for cystic fibrosis. KB407 is an inhaled, repeat-dose gene therapy produc
   Krystal Biotech’s KB407 Granted Orphan Drug Designation by the FDA to Treat Patients With Cystic Fibrosis  2020/08/17 20:01:00 GlobeNewswire
The company is on track to file an IND for KB407 in 2021
   Krystal Biotech Announces Initiation of Pivotal Phase 3 Study of Beremagene Geperpavec in Patients with Dystrophic Epidermolysis Bullosa  2020/07/28 20:44:49 GlobeNewswire
The randomized, double-blind GEM-3 trial will compare repeat dosing of either B-VEC or placebo in approximately 30 dystrophic epidermolysis bullosa (DEB)…
   Krystal Biotech Appoints Whitney Ijem as Senior Vice President, Strategy and Business Development  2020/07/20 12:00:00 GlobeNewswire
PITTSBURGH, July 20, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (Nasdaq:KRYS), a fully integrated gene therapy company driven by its proprietary,…
   The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight  2020/05/10 19:40:37 Benzinga
The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB ) gained about 6% for the week. Large-cap pharma names AstraZeneca plc (NYSE: AZN ) and Novartis AG (NYSE: NVS ) received FDA nods for their heart failure and lung cancer therapies, respectively. After receiving emergency use authorization from the FDA in the U.S., Gilead Sciences, Inc.'s (NASDAQ: GILD ) remdesivir obtained full regulatory approval in Japan. Moderna Inc (NASDAQ: MRNA ) received the OK to proceed with the Phase 2 trial of its mRNA coronavirus vaccine candidate mRNA-1273. The following are the key events and catalysts that biotech investors need to watch in the coming week. Conferences Bank of America Securities 2020 HealthCare Virtual Conference: May 12-14 American Society of Gene and Cell Therapy, or ASGCT, 23rd Virtual Annual Meeting: May 12-15 2020 Society for Investigative Dermatology, or SID, Annual Meeting Virtual Conference: May 13-16 Society for Cardiovascular Angiography and Interventions, or SCAI, 2020 Virtual Conference, Scientific Sessions: May 14-16 PDUFA Dates Clovis Oncology Inc (NASDAQ: CLVS ) awaits the FDA nod for an expanded indication for its cancer therapy Rubraca .
   Krystal biotech’s gene therapy an Orphan Drug in U.S. for cystic fibrosis (NASDAQ:KRYS)  2020/08/17 20:10:08 Seeking Alpha
The FDA has designated Orphan drug tag to Krystal Biotech (NASDAQ:KRYS), to KB407 for cystic fibrosis. KB407 is an inhaled, repeat-dose gene therapy produc
   Krystal Biotech’s KB407 Granted Orphan Drug Designation by the FDA to Treat Patients With Cystic Fibrosis  2020/08/17 20:01:00 GlobeNewswire
The company is on track to file an IND for KB407 in 2021
   Krystal Biotech Announces Initiation of Pivotal Phase 3 Study of Beremagene Geperpavec in Patients with Dystrophic Epidermolysis Bullosa  2020/07/28 20:44:49 GlobeNewswire
The randomized, double-blind GEM-3 trial will compare repeat dosing of either B-VEC or placebo in approximately 30 dystrophic epidermolysis bullosa (DEB)…
   Krystal Biotech Appoints Whitney Ijem as Senior Vice President, Strategy and Business Development  2020/07/20 12:00:00 GlobeNewswire
PITTSBURGH, July 20, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (Nasdaq:KRYS), a fully integrated gene therapy company driven by its proprietary,…
   The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight  2020/05/10 19:40:37 Benzinga
The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB ) gained about 6% for the week. Large-cap pharma names AstraZeneca plc (NYSE: AZN ) and Novartis AG (NYSE: NVS ) received FDA nods for their heart failure and lung cancer therapies, respectively. After receiving emergency use authorization from the FDA in the U.S., Gilead Sciences, Inc.'s (NASDAQ: GILD ) remdesivir obtained full regulatory approval in Japan. Moderna Inc (NASDAQ: MRNA ) received the OK to proceed with the Phase 2 trial of its mRNA coronavirus vaccine candidate mRNA-1273. The following are the key events and catalysts that biotech investors need to watch in the coming week. Conferences Bank of America Securities 2020 HealthCare Virtual Conference: May 12-14 American Society of Gene and Cell Therapy, or ASGCT, 23rd Virtual Annual Meeting: May 12-15 2020 Society for Investigative Dermatology, or SID, Annual Meeting Virtual Conference: May 13-16 Society for Cardiovascular Angiography and Interventions, or SCAI, 2020 Virtual Conference, Scientific Sessions: May 14-16 PDUFA Dates Clovis Oncology Inc (NASDAQ: CLVS ) awaits the FDA nod for an expanded indication for its cancer therapy Rubraca .

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 クリスタル・バイオテック KRYS Krystal Biotech Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)